Zepto® has been demonstrated in a FDA clinical trial to be safe and effective.  No change in corneal incision size was observed after Zepto use in 70% of cases, and a mean enlargement of 30 micron was encountered in 30% of cases.  No differences in ocular condition have been observed after Zepto use compared to CCC, with a peak temperature increase of 1-2°C for a fraction of a second.

View Miyake-Apple Imaging of Zonular Tissue During Zepto Use

View Temperature Testing and Data Sheet

Download Peer Reviewed Publication of Zepto Capsulotomy Strength Testing

Download Peer Reviewed Publication with Zepto Product Performance Review

NEWS

28 Jun Streamlined method for anchoring cataract surgery and intraocular lens centration on the patient’s visual axis In this article, Dr. Vance Thompson describes "an intraoperative ... read more ›
12 Jun Mynosys Announces Significantly Less Posterior Capsular Opacification in Patients After Zepto® Capsulotomy FREMONT, CALIF. (PRWEB) JUNE 06, 2018 Mynosys Cellular Devices ... read more ›
31 May Aequus Announces Official Launch of Zepto Capsulotomy System in Canada to be June 1, 2018 Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” ... read more ›

FEATURED VIDEO